Ascensia Diabetes Care and Voluntis Announce Technology Partnership to Help Optimize Insulin Management for People With Type 2 Diabetes

0
1235

BASEL, thepresidentpost.com – Ascensia Diabetes Care and Voluntis today announced a global technology partnership designed to help improve the lives of people with type 2 diabetes by optimizing insulin management. This collaboration will connect the Voluntis basal insulin management solution for people with Type 2 diabetes, the Insulia® Diabetes Management Companion, with the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems (BGMS) from Ascensia.

Under the terms of the agreement, the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE meters will connect via Bluetooth to Insulia® and the blood glucose readings will be used to calculate basal insulin dosing for people with Type 2 diabetes. By linking highly accurate blood glucose data to this basal insulin manager, the two companies aim to empower self-management for patients and help optimize insulin management in the real-world to improve outcomes. The integration between these two solutions is expected to be available for people with diabetes and healthcare professionals in Q4 2017.

“Type 2 diabetes is a complex condition, especially for people using insulin therapy as part of their management. We’re excited to be working together with Voluntis to empower people with Type 2 diabetes by helping them to better manage their insulin treatment. This partnership helps us move further towards our ambition of providing integrated diabetes management, which we see as the future. It is our first partnership in the area of medication management, which is a critical component of integrated diabetes management, and we see Voluntis as a key partner in helping to deliver this goal,” explained Michael Kloss, CEO of Ascensia Diabetes Care.

“We are delighted to start this collaboration with Ascensia in order to provide a seamless combination of Bluetooth-enabled blood glucose monitoring systems with digital insulin therapy optimization,” said Pierre Leurent, CEO of Voluntis. “Joining forces will help us simplify how people manage their blood sugars from end-to-end so they can vastly improve their quality of life,” he added.

Michael added, “The simplicity and effectiveness of the Insulia® solution combined with the remarkable accuracy of the CONTOUR®NEXT ONE and CONTOUR®PLUS ONE blood glucose monitoring systems, has the ability to meaningfully impact the lives of people living with diabetes, and as a result, this could lead to better outcomes.”

Insulia® Diabetes Management Companion is a prescription-only medical device that provides people with Type 2 diabetes with insulin dose recommendations and educational coaching messages, through a smartphone app, based on blood glucose values and other diabetes-related data. Insulia® supports a wide variety of treatment plan configurations and evidence-based insulin adjustment rules used in routine clinical practice. The personalized treatment plan is initially set-up by the healthcare professional, based on an individual’s profile, insulin prescription and blood glucose targets. The dose adjustment algorithm is embedded in the app requiring no further validation from healthcare professionals after the system’s initial setup. The patient data can then be automatically shared with the healthcare team, who can remotely monitor the patient’s progress toward their goal thanks to tailored notifications. The solution has received both FDA 510(k) clearance from the US FDA and CE Mark approval in Europe in November 2016.

The CONTOUR®NEXT ONE and CONTOUR®PLUS ONE systems each feature a highly accurate easy-to-use blood glucose smart meter that links to a mobile device via Bluetooth® connectivity. The meter connects to the CONTOUR™ DIABETES app, a mobile app that collects, stores and analyzes patient blood glucose measurements delivered to it by the meter. The CONTOUR®NEXT ONE and CONTOUR®PLUS ONE BGMSs received CE Mark approval in Europe in April 2016, and the CONTOUR®NEXT ONE BGMS received 510(k) clearance from the FDA in November 2016. The CONTOUR™ DIABETES app will be available for download from the Apple App Store (iOS) and Google Play (Android).